The latest GI-cancer news from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in GI-cancer.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

Patient-Derived Organoids Can Recapitulate Patient Responses in the Clinic

Comparison of organoid drug responses with how the patients with metastatic gastrointestinal cancers responded in the clinic

Read full article (External website)

Death due to cancer on the decline for most tumours in Europe

The exceptions are death due to lung and pancreatic carcinoma in women which are both still on the rise, according to a new study, published in Annals of Oncology on the 19th of March 2018.

Researchers predict that the death rates for most types of cancer will be lower in 2018 when compared to 2012 in the European Union.

The study, led by Carlo La Vecchia (MD) of the University of Milan, shows that death due to colorectal cancer (CRC) is on the decline in Europe. The researchers call the drop in death-rates of CRC, which is the most common cause of cancer-death in non-smoking males and females, one of the major achievements in the management of oncologic diseases over the recent years.

Key numbers for CRC:

  • CRC is the second highest cause of cancer-death: 177,400 (male: 98,000 in men; female 79,400);
  • Due to the ageing population, the absolute quantities of fatalities have risen since 2012;
  • In contrast, the age-standardised rates will decrease by 6.7% in men (15.8 per 100,000) and 7.5% in women (9.2 per 100,000).

Risk factors for CRC include:

  • Tobacco
  • Alcohol
  • Obesity
  • Diabetes
  • Sedentary lifestyle
  • Unhealthy diet

The use of oral contraceptives and hormone-replacement therapy in women may partly explain the decreased risk in females. Furthermore, the use of aspirin for prevention of cardiovascular disease and effective screening may further contribute to a decrease in the incidence of the disease in both sexes.

Key numbers for all cancers in Europe:

  • In 2018, 1.4 million cancer deaths are predicted, up from 1.3 million in 2012.
  • Death-rates have fallen by 10.3% in men and 5% in women
  • Age-standardised death rates in 2018 are predicted to be 130 per 100,000 for men and 84 per 100,000 for women.


  1. Malvezzi M et al. Ann Oncol. doi:10.1093/annonc/mdy033

Precision Medicine Impact Grows in GI Cancer Paradigm

Bert H. O’Neil, MD, the role of molecular testing throughout GI cancers and highlighted the current and developing treatment landscape for patients with colorectal cancer.

Read full article (External website)

Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline

Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.

Read full article (External website)

Immunotherapy Arrives in Gastric Cancer

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Read full article (External website)

Priority Review Granted by FDA for Nivolumab Plus Ipilimumab Combo for MSI-H/dMMR CRC

There has been a supplemental biologics license application (sBLA) granted priority review by the FDA for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cases of metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Combination of Atezolizumab and Cobimetinib Active in mCRC

The combinations of atezolizumab and cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer. Results from a 2-stage phase Ib trial presented at the 2018 Gastrointestinal Cancers Symposium demonstrated an overall response rate of 8% (n = 7). All responses were partial responses.

Read full article (External website)

Expert Sheds Light on Recent Advances in mCRC

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Read full article (External website)

EMA Suggests Extension of Therapeutic Indications for Denosumab

Extension of indication includes the avoidance of skeletal-related events in grown-ups with late-stage malignancies involving the bone

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending towards a change in the marketing authorisation for denosumab (licensee: Amgen Europe BV).

The following extension of the label was adopted by the CHMP:

  • Prevention of skeletal-related events in adults with advanced malignancies involving bone (e.g. pathological fracture, radiation to the bone, spinal cord compression, or surgery to the bone).

Previously, denosumab was only indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.


FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer

Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).


What You Need to Know About Colorectal Cancer

2018-03-13 21:00:00

March 13, 2018

Being diagnosed with colorectal cancer can be scary and confusing. Dr. Jeffrey Meyerhardt, an expert in colorectal cancer, describes the 4 questions that any newly diagnosed patient should ask.